Role of high-dose chemotherapy with autologous stem-cell rescue in men with previously treated germ cell tumors

Lance C. Pagliaro

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A 39-year-old, previously healthy man presented with a left testicular mass, confirmed on ultrasound. He underwent left inguinal orchiectomy, which disclosed testicular carcinoma composed of 90% choriocarcinoma, 9% seminoma, and 1% teratoma. Imaging revealed numerous metastases in the lungs, liver, and brain. Prechemotherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropin (hCG) 151,111 IU/L, and lactate dehydrogenase 588 U/L. He received four courses of etoposide, ifosfamide, and cisplatin chemotherapy, given without bleomycin because of the anticipated need for postchemotherapy thoracic surgery. He had an incomplete response to induction chemotherapy. The serum hCG level was 8.1 IU/L, and there were residual lesions in the liver and lungs whereas the brain metastases had nearly resolved. His Eastern Cooperative Oncology Group performance status was zero.He had no symptoms of ototoxicity or peripheral neurotoxicity. Repeat serumhCG levels after chemotherapy were 12.3 IU/L at 2 weeks and 325 IU/L at 4 weeks. He was referred to discuss optimal ongoing treatment.

Original languageEnglish (US)
Pages (from-to)1036-1040
Number of pages5
JournalJournal of Clinical Oncology
Volume35
Issue number10
DOIs
StatePublished - Apr 1 2017

Fingerprint

Germ Cell and Embryonal Neoplasms
Chorionic Gonadotropin
Stem Cells
Neoplasm Metastasis
Drug Therapy
Lung
Ifosfamide
Seminoma
Choriocarcinoma
Induction Chemotherapy
Orchiectomy
Groin
Liver
Teratoma
Bleomycin
Brain
alpha-Fetoproteins
Etoposide
Tumor Biomarkers
L-Lactate Dehydrogenase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Role of high-dose chemotherapy with autologous stem-cell rescue in men with previously treated germ cell tumors. / Pagliaro, Lance C.

In: Journal of Clinical Oncology, Vol. 35, No. 10, 01.04.2017, p. 1036-1040.

Research output: Contribution to journalArticle

@article{e07b271464ca4a7498a690d77fb7265f,
title = "Role of high-dose chemotherapy with autologous stem-cell rescue in men with previously treated germ cell tumors",
abstract = "A 39-year-old, previously healthy man presented with a left testicular mass, confirmed on ultrasound. He underwent left inguinal orchiectomy, which disclosed testicular carcinoma composed of 90{\%} choriocarcinoma, 9{\%} seminoma, and 1{\%} teratoma. Imaging revealed numerous metastases in the lungs, liver, and brain. Prechemotherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropin (hCG) 151,111 IU/L, and lactate dehydrogenase 588 U/L. He received four courses of etoposide, ifosfamide, and cisplatin chemotherapy, given without bleomycin because of the anticipated need for postchemotherapy thoracic surgery. He had an incomplete response to induction chemotherapy. The serum hCG level was 8.1 IU/L, and there were residual lesions in the liver and lungs whereas the brain metastases had nearly resolved. His Eastern Cooperative Oncology Group performance status was zero.He had no symptoms of ototoxicity or peripheral neurotoxicity. Repeat serumhCG levels after chemotherapy were 12.3 IU/L at 2 weeks and 325 IU/L at 4 weeks. He was referred to discuss optimal ongoing treatment.",
author = "Pagliaro, {Lance C.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1200/JCO.2016.70.6523",
language = "English (US)",
volume = "35",
pages = "1036--1040",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Role of high-dose chemotherapy with autologous stem-cell rescue in men with previously treated germ cell tumors

AU - Pagliaro, Lance C.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - A 39-year-old, previously healthy man presented with a left testicular mass, confirmed on ultrasound. He underwent left inguinal orchiectomy, which disclosed testicular carcinoma composed of 90% choriocarcinoma, 9% seminoma, and 1% teratoma. Imaging revealed numerous metastases in the lungs, liver, and brain. Prechemotherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropin (hCG) 151,111 IU/L, and lactate dehydrogenase 588 U/L. He received four courses of etoposide, ifosfamide, and cisplatin chemotherapy, given without bleomycin because of the anticipated need for postchemotherapy thoracic surgery. He had an incomplete response to induction chemotherapy. The serum hCG level was 8.1 IU/L, and there were residual lesions in the liver and lungs whereas the brain metastases had nearly resolved. His Eastern Cooperative Oncology Group performance status was zero.He had no symptoms of ototoxicity or peripheral neurotoxicity. Repeat serumhCG levels after chemotherapy were 12.3 IU/L at 2 weeks and 325 IU/L at 4 weeks. He was referred to discuss optimal ongoing treatment.

AB - A 39-year-old, previously healthy man presented with a left testicular mass, confirmed on ultrasound. He underwent left inguinal orchiectomy, which disclosed testicular carcinoma composed of 90% choriocarcinoma, 9% seminoma, and 1% teratoma. Imaging revealed numerous metastases in the lungs, liver, and brain. Prechemotherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropin (hCG) 151,111 IU/L, and lactate dehydrogenase 588 U/L. He received four courses of etoposide, ifosfamide, and cisplatin chemotherapy, given without bleomycin because of the anticipated need for postchemotherapy thoracic surgery. He had an incomplete response to induction chemotherapy. The serum hCG level was 8.1 IU/L, and there were residual lesions in the liver and lungs whereas the brain metastases had nearly resolved. His Eastern Cooperative Oncology Group performance status was zero.He had no symptoms of ototoxicity or peripheral neurotoxicity. Repeat serumhCG levels after chemotherapy were 12.3 IU/L at 2 weeks and 325 IU/L at 4 weeks. He was referred to discuss optimal ongoing treatment.

UR - http://www.scopus.com/inward/record.url?scp=85016587012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016587012&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.70.6523

DO - 10.1200/JCO.2016.70.6523

M3 - Article

C2 - 27992270

AN - SCOPUS:85016587012

VL - 35

SP - 1036

EP - 1040

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -